Stock Financial Ratios, Dividends, Split History

MENT / Mentor Graphics Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)4,115.64
Book Value ($M)1,375.68
Book Value / Share12.45
Price / Book2.99
NCAV ($M)148.38
NCAV / Share1.34
Price / NCAV27.74
Share Statistics
Common Shares Outstanding 110,487,092
Weighted Average Number Of Shares Outstanding Basic 108,795,000
Common Stock Shares Outstanding 110,383,000
Weighted Average Number Of Diluted Shares Outstanding 114,322,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.11
Return on Assets (ROA)0.08
Return on Equity (ROE)0.12
Balance Sheet (mrq) ($M)
Quick Ratio1.32
Current Ratio1.34
Income Statement (mra) ($M)
Maintenance Revenue488,017,000.00
Licenses Revenue794,450,000.00
Operating Income203.08
Net Income154.87
Earnings Per Share Basic1.42
Earnings Per Share Diluted1.37
Cash Flow Statement (mra) ($M)
Cash From Operations321.81
Cash from Investing-72.05
Cash from Financing-72.05
Identifiers and Descriptors
Central Index Key (CIK)701811
Related CUSIPS
587200956 587200906

Split History

Stock splits are used by Mentor Graphics Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

Cadence's (CDNS) CEO Lip-Bu Tan on Q1 2018 Results - Earnings Call Transcript

2018-04-24 seekingalpha
Cadence Design Systems, Inc. (NASDAQ:CDNS) Q1 2018 Earnings Conference Call April 23, 2018 5:00 PM ET (11-0)

Cadence Design Systems: Good Bet On Earnings Or Buyout

2018-04-09 seekingalpha
Demand for new innovations and products in IoT, A.I., cloud, security, and mobile devices is fueling the semiconductor industry boom. (11-1)

Synopsys Refills Share Buyback Fund to Reach $500M Limit

2018-04-06 zacks
Synopsys Inc. (SNPS - Free Report) recently announced that its board of directors has replenished its ongoing share repurchase program to its limit of $500 million. Notably, the stock repurchase program has been in effect since 2002 and the allotted capital has been refilled depending on the availability of funds. However, Synopsys is not obligated to buy back any specific number of shares and the program may be terminated depending on the company’s decision. (80-0)

Reasons Why You Should Get Rid of Cadence (CDNS) Stock Now

2018-04-02 zacks
If you are still holding on to shares of Cadence Design Systems, Inc. (CDNS - Free Report) in your portfolio, it is time you dump them as chances of favorable returns in the near term appear bleak. (142-0)

CUSIP: 587200106